Antioxidative and anti-inflammatory activities of paeoniflorin and oxypaeoniflora on AGEs-induced mesangial cell damage

Planta Med. 2013 Sep;79(14):1319-23. doi: 10.1055/s-0033-1350649. Epub 2013 Jul 23.

Abstract

Paeonia suffruticosa, an important traditional herbal medicine, has been reported to prevent the pathogenesis of diabetic nephropathy through modulating advanced glycation end products-induced inflammatory and oxidative stress responses. However, little was known about the protective effect of the two major compounds in P. suffruticosa, paeoniflorin and oxypaeoniflora, on advanced glycation end products-induced mesangial cell damage. In the present study, we investigated the protective activities of paeoniflorin and oxypaeoniflora on advanced glycation end product-induced oxidative stress and inflammation in mesangial cells HBZY-1. The IC50 values of paeoniflorin and oxypaeoniflora for inhibiting 2,2'-azinobis-(3-thylbenzothiazoline-6-sulfonic acid) formation were 4.197 × 10-4 M and 1.002 × 10-4 M, respectively. The pretreatment with paeoniflorin and oxypaeoniflora (10-8-10-4 M) significantly increased advanced glycation end product-induced glutathione peroxidase and catalase activities. In the coculture system of HBZY-1 and macrophages, paeoniflorin and oxypaeoniflora could inhibit remarkably the migration of macrophages. Furthermore, paeniflorin and oxypaeniflora attenuated markedly advanced glycation end products-induced inflammation cytokines interleukin-6 and monocyte chemoattractant protein-1 levels in ELISA and western blot analysis in a dose-dependent manner. Taken together, our data provided the reliable evidence that paeniflorin and oxypaeniflora were able to attenuate advanced glycation end products-induced oxidative damage and inflammation in mesangial cells. Paeniflorin and oxypaeniflora might therefore have a beneficial effect in the treatment of diabetic nephropathy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / isolation & purification
  • Anti-Inflammatory Agents / pharmacology*
  • Anti-Inflammatory Agents / therapeutic use
  • Antioxidants / isolation & purification
  • Antioxidants / metabolism
  • Antioxidants / pharmacology*
  • Antioxidants / therapeutic use
  • Benzoates / isolation & purification
  • Benzoates / pharmacology*
  • Benzoates / therapeutic use
  • Bridged-Ring Compounds / isolation & purification
  • Bridged-Ring Compounds / pharmacology*
  • Bridged-Ring Compounds / therapeutic use
  • Catalase / metabolism
  • Chemokine CCL2 / metabolism
  • Diabetic Nephropathies / drug therapy
  • Diabetic Nephropathies / metabolism
  • Diabetic Nephropathies / pathology
  • Dose-Response Relationship, Drug
  • Drugs, Chinese Herbal / isolation & purification
  • Drugs, Chinese Herbal / pharmacology*
  • Drugs, Chinese Herbal / therapeutic use
  • Glucosides / isolation & purification
  • Glucosides / pharmacology*
  • Glucosides / therapeutic use
  • Glutathione Peroxidase / metabolism
  • Glycation End Products, Advanced / metabolism*
  • Inflammation / drug therapy
  • Inflammation / metabolism
  • Inhibitory Concentration 50
  • Interleukin-6 / metabolism
  • Macrophages / drug effects
  • Mesangial Cells / drug effects*
  • Mesangial Cells / metabolism
  • Mesangial Cells / pathology
  • Monoterpenes
  • Oxidative Stress / drug effects
  • Paeonia / chemistry*
  • Phytotherapy
  • Rats

Substances

  • Anti-Inflammatory Agents
  • Antioxidants
  • Benzoates
  • Bridged-Ring Compounds
  • Chemokine CCL2
  • Drugs, Chinese Herbal
  • Glucosides
  • Glycation End Products, Advanced
  • Interleukin-6
  • Monoterpenes
  • peoniflorin
  • oxypaeoniflora
  • Catalase
  • Glutathione Peroxidase